Clinical Trials Directory

Trials / Completed

CompletedNCT00356798

Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects

The Phase-I Clinical Trial Protocol for the Pandemic Inactivated Influenza Vaccine

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
120 (planned)
Sponsor
Sinovac Biotech Co., Ltd · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole virion H5N1 vaccine with aluminium hydroxide adjuvant.

Conditions

Interventions

TypeNameDescription
BIOLOGICALan inactivated whole virion H5N1 vaccine, adjuvanted

Timeline

Start date
2005-12-01
Completion
2006-04-01
First posted
2006-07-26
Last updated
2007-11-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT00356798. Inclusion in this directory is not an endorsement.

Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects (NCT00356798) · Clinical Trials Directory